Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells.

Notch signaling is an evolutionarily conserved pathway involved in cell fate control during development, stem cell self-renewal and postnatal tissue differentiation. Roles for Notch in carcinogenesis, in the biology of cancer stem cells, tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) have been reported. This mini-review describes the role of Notch signaling deregulation in EMT and tumor aggressiveness. We describe how accumulated evidence suggests that Notch inhibition is an attractive strategy for the treatment of several cancers, at least in part because of its potential to reverse or prevent EMT.

[1]  G. Goodall,et al.  The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. , 2011, The Journal of clinical investigation.

[2]  英樹 仁井見.  Notch signaling is necessary for epithelial growth arrest by TGF-β , 2007 .

[3]  H. Höfler,et al.  Analysis of the E-Cadherin Repressor Snail in Primary Human Cancers , 2007, Cells Tissues Organs.

[4]  Fei Xing,et al.  Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells , 2011, Oncogene.

[5]  Jun-ling Liu,et al.  Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cells , 2012, Journal of cellular biochemistry.

[6]  G. van der Pluijm.  Epithelial plasticity, cancer stem cells and bone metastasis formation. , 2011, Bone.

[7]  U. Lendahl,et al.  Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.

[8]  J. Aster,et al.  MAML 1 , a human homologue of Drosophila Mastermind , is a transcriptional coactivator for NOTCH receptors , 2000 .

[9]  James D. Griffin,et al.  MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors , 2000, Nature Genetics.

[10]  U. Lendahl,et al.  Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. , 2010, Experimental Cell Research.

[11]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[12]  A Cumano,et al.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.

[13]  J. Boulter,et al.  Jagged2: a serrate-like gene expressed during rat embryogenesis. , 1996, Developmental biology.

[14]  Xudong Dai,et al.  Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. , 2009, Cancer research.

[15]  J. Izbicki,et al.  Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. , 2011, Cancer research.

[16]  A. Ferrando,et al.  Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia , 2012, Molecular Cancer Therapeutics.

[17]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[18]  S. Artavanis-Tsakonas,et al.  Intracellular Cleavage of Notch Leads to a Heterodimeric Receptor on the Plasma Membrane , 1997, Cell.

[19]  Pamela A. Hoodless,et al.  Slug is a direct Notch target required for initiation of cardiac cushion cellularization , 2008, The Journal of cell biology.

[20]  R. Beddington,et al.  Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. , 1997, Development.

[21]  U. Gündüz,et al.  Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  Chindo Hicks,et al.  Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. , 2008, Cancer research.

[23]  T. Golde,et al.  Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy , 2012, Vascular cell.

[24]  R. Clarke,et al.  Tumor and Stem Cell Biology Cancer Research Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch 4 Receptor , 2010 .

[25]  Wei Chen,et al.  Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. , 2010, American journal of translational research.

[26]  J. Zavadil,et al.  Integration of TGF‐β/Smad and Jagged1/Notch signalling in epithelial‐to‐mesenchymal transition , 2004 .

[27]  D. Carvajal,et al.  Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. , 2009, Cancer research.

[28]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[29]  J. Thiery.  [Epithelial-mesenchymal transitions in cancer onset and progression]. , 2009, Bulletin de l'Academie nationale de medecine.

[30]  M. Gessler,et al.  Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. , 2000, Biochemical and biophysical research communications.

[31]  A. Papavassiliou,et al.  Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions , 2012, Medicinal research reviews.

[32]  Marina Kriajevska,et al.  SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer , 2009, Proceedings of the National Academy of Sciences.

[33]  B. Bao,et al.  Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. , 2011, Cancer letters.

[34]  O. De Wever,et al.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[35]  H. Kajiyama,et al.  Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. , 2007, International journal of oncology.

[36]  G. Lockwood,et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. , 2005, Cancer research.

[37]  Zhiwei Wang,et al.  Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells , 2010, PloS one.

[38]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[39]  E. Bresnick,et al.  Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells , 2013, Oncogenesis.

[40]  K. Albain,et al.  Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence , 2011, British Journal of Cancer.

[41]  U. Lendahl,et al.  Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways , 2008, Proceedings of the National Academy of Sciences.

[42]  Simone Brabletz,et al.  The ZEB1/miR‐200 feedback loop controls Notch signalling in cancer cells , 2011, The EMBO journal.

[43]  U. Lendahl,et al.  Hypoxia requires notch signaling to maintain the undifferentiated cell state. , 2005, Developmental cell.

[44]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[45]  Zhiwei Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.

[46]  J. Lewin,et al.  Abstract 410: Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. , 2013 .

[47]  Connie J. Eaves,et al.  Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin , 2007 .

[48]  A. Capobianco,et al.  Induction of Cyclin D1 Transcription and CDK2 Activity by Notchic: Implication for Cell Cycle Disruption in Transformation by Notchic , 2001, Molecular and Cellular Biology.

[49]  Ian Krop,et al.  Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.

[50]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[51]  J. Hsieh,et al.  CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Zavadil,et al.  Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. , 2004, The EMBO journal.

[53]  R. Kalluri,et al.  The role of endothelial-to-mesenchymal transition in cancer progression , 2008, British Journal of Cancer.

[54]  A. Karsan,et al.  Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. , 2007, The Journal of experimental medicine.

[55]  J. Boulter,et al.  Jagged: A mammalian ligand that activates notch1 , 1995, Cell.

[56]  Raphael Kopan,et al.  Murine Notch Homologs (N1–4) Undergo Presenilin-dependent Proteolysis* , 2001, The Journal of Biological Chemistry.

[57]  L. Miele,et al.  Notch inhibitors for cancer treatment. , 2013, Pharmacology & therapeutics.